跳至主要内容
临床试验/NCT05038878
NCT05038878终止4 期

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

Icahn School of Medicine at Mount Sinai1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2021年7月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
4
试验地点
1
主要终点
Number of Participants With Change in Cortisol Level

研究概览

简要总结

The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and quality of life in a female patient with mild hypercortisolism from adrenal overproduction of cortisol. Many people with adrenal nodules, or non-cancerous growths in the adrenal glands, have mildly elevated cortisol levels. Cortisol is a hormone normally made by the adrenal glands. It is increasingly being recognized that even mild elevations in cortisol levels can negatively impact blood glucose levels, serum cholesterol levels, weight and other metabolic parameters. This can lead to an increase in risk for cardiovascular disease. The study team is trying to determine if the medication Elagolix might be an effective treatment for post-menopausal females with mild hypercortisolism. Elagolix is a medication used to treat a medical condition called endometriosis by decreasing the body's production of sex hormones. Growth of adrenal adenomas is thought to be driven by such sex hormones. Therefore, by decreasing production of these hormones, the study team hopes to treat hypercortisolism caused by adrenal adenomas.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • Post-menopausal women that have incidentally found adrenal adenomas with benign appearing characteristics on imaging (<4 cm, non-contrast CT <10 HU and/or lipid rich and benign appearing on MRI)
  • Absence of anti-anabolic clinical features of overt Cushing's signs (proximal muscle weakness, >three ecchymoses, hyperpigmented striae) and 2 of 3 of the following:
  • Elevated 24 hr urine free cortisol (UFC) above the upper limit of normal (>50 mcg/24 hours) in at least two complete 24-hour tests and/or
  • Late night salivary cortisol more than upper limit of normal in at least two tests and/or
  • an abnormal dexamethasone suppression defined as post 1mg dexamethasone suppression test serum cortisol concentration of >1.8 mcg/ml
  • Clinic status of cessation of menses for 12 mo in a previously cycling woman and reflecting complete or nearly complete permanent cessation of ovarian function and fertility (26).
  • Patients with osteoporosis that are not receiving treatment with either antiresorptive medications (bisphosphonates, denosumab) or anabolic agents (teriparitide, abaloparatide or romosozumab)

排除标准

  • 未提供

研究组 & 干预措施

GnRH antagonist (Elagolix)

Experimental

Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression

干预措施: Elagolix (Drug)

结局指标

主要结局

Number of Participants With Change in Cortisol Level

时间窗: baseline and 6 months

Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed. Number of participants with interval improvement and normalization of late-night salivary results after 6 months of treatment.

Change in Cortisol Level

时间窗: baseline and 6 months

Cortisol level after dexamethasone suppression test which measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed. Cortisol secretion as reported below by assessment of pre-treatment and post-treatment of late-night salivary cortisol levels (normal midnight values: \<0.010 - 0.090)

Number of Participants With Change in 24 Hour Urine Free Cortisol Level

时间窗: Baseline and 6 months

24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland. Number of participants with improvement in 24-hour urinary free cortisol after treatment (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).

24 Hour Urine Free Cortisol Level

时间窗: Baseline and 6 months

24 hour urine free cortisol measurements. The cortisol urine test measures the level of cortisol in the urine. Cortisol is a glucocorticoid (steroid) hormone produced by the adrenal gland. Cortisol secretion as reported below by assessment of pre-treatment and post-treatment of 24-hour urinary cortisol levels (normal 24-hr urinary cortisol is between 6 - 42 ug/24 hr).

Number of Participants With Change in Adenoma Size as Compared to Baseline

时间窗: Baseline and 6 months

All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.

Change in Adenoma Size as Compared to Baseline

时间窗: Baseline and 6 months

All patients will have baseline imaging (CT or MRI) within 6 months to start of treatment and then will have repeat imaging with CT abdomen without contrast at 6 months to determine the effect of elagolix treatment on adrenal adenoma size and imaging characteristics. The images will be reviewed by a dedicated adrenal radiologist for consistency.

次要结局

  • Change in Body Weight as Compared to Baseline(baseline and 6 months)
  • Change in Body Weight for Those Participants Who Lost Weight(baseline and 6 months)
  • Trunk Fat(baseline and 6 months)
  • Number of Participants With Vertebral Fractures(baseline and 6 months)
  • The Cushing's Quality of Life Questionnaire(baseline and 6 months)
  • Beck's Depression Scale(baseline and 6 months)
  • State Trait Anxiety Inventory (STAI)(baseline and 6 months)
  • Preserved Glucose(baseline and 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alice C. Levine

Professor, Medicine - Endocrinology, Diabetes and Bone Disease

Icahn School of Medicine at Mount Sinai

研究点 (1)

Loading locations...

相似试验